Sadovsky Richard, Collins Nancy, Tighe Ann P, Safeer Richard S, Morris Charlene M, Brunton Stephen A
SUNY Health Science Center, Brooklyn College of Medicine, Brooklyn, NY 11203, USA.
Postgrad Med. 2008 Jul;120(2):92-100. doi: 10.3810/pgm.2008.07.1796.
Although there is an enormous amount of information available on omega-3 fatty acids, it is sometimes misleading, contradictory, and unsupported by scientific fact. Consumers and medical professionals may be confused regarding the potential value of omega-3 fatty acid supplements, despite having either read or heard about fi sh oil consumption and/or omega-3 fatty acid benefits and risks. The availability of a prescription formulation of omega-3-acid ethyl esters (P-OM3) has provided important new information that helps to dispel the myths and alleviate concerns surrounding the use of omega-3 fatty acids in clinical practice. The safety and efficacy of P-OM3, but not dietary-supplement omega-3 fatty acids, are documented in placebo-controlled trials. In general, studies using Food and Drug Administration-approved dosages of P-OM3 have not substantiated various myths surrounding the negative effects of omega-3 fatty acids. Thus, there are now evidence-based clinical guidelines for the use of omega-3 fatty acids in clinical practice.
尽管关于ω-3脂肪酸有大量信息,但这些信息有时具有误导性、相互矛盾且缺乏科学依据。消费者和医学专业人员可能会对ω-3脂肪酸补充剂的潜在价值感到困惑,尽管他们已经阅读或听说过食用鱼油和/或ω-3脂肪酸的益处及风险。ω-3-酸乙酯的处方制剂(P-OM3)的出现提供了重要的新信息,有助于消除围绕在临床实践中使用ω-3脂肪酸的误解并减轻担忧。P-OM3的安全性和有效性在安慰剂对照试验中有记录,而膳食补充剂中的ω-3脂肪酸则没有。一般来说,使用美国食品药品监督管理局批准剂量的P-OM3进行的研究并未证实围绕ω-3脂肪酸负面影响的各种误解。因此,现在有了基于证据的临床实践中使用ω-3脂肪酸的指南。